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repair in high-risk patients: Results from the
Swedish Vascular Registry
Carl Magnus Wahlgren, MD, PhD, and Jonas Malmstedt, MD, on behalf of the Swedish Vascular
Registry, Stockholm, Sweden
Background: The management of infrarenal aortic aneurysms in high-risk patients remains a challenge. Endovascular
aneurysm repair (EVAR) is associated with superior short-term mortality rates but unclear long-term results and has not
been shown to improve survival in patients unfit for open repair (OR). The aim of this population-based study was to
evaluate the outcome after elective EVAR compared with OR in a high-risk patient cohort.
Methods: Prospectively collected data from January 2000 to December 2006 were retrieved from the Swedish Vascular
Registry. The high-risk cohort was defined as age >60 years, American Anesthesiologists Association (ASA) class 3 or 4,
and at least one cardiac, pulmonary, or renal comorbidity. These criteria weremet by 217 of 1000 EVAR patients and 483
of 2831 OR patients. Primary end points were 30-day and 1-year all-cause mortality. Kaplan-Meier curves for survival
and multivariate Cox regression analyses were performed.
Results:The crude 30-day and1-year all-causemortality rates forEVARvsOR for thewhole treatment group (n3831)were
1.8% vs 2.8% and 8.0% vs 7.2%, respectively. In the high-risk cohort (n  700), EVAR patients were approximately 2 years
older and renal insufficiency and diabetes mellitus were more common, and smoking was more prevalent in the OR group.
About two-thirds of EVARprocedures were performed at university hospitals and one-half ofORprocedures were performed
at county hospitals. In the high-risk cohort, there was no difference in mortality at 30-days (EVAR, 4.6% vs OR, 3.3%), but
OR had lower 1-year mortality (8.5% vs 15.9%; P  .003). More bleeding complications occurred in the EVAR group, but
more pulmonary complications occurred in the OR group; however, there was no difference in cardiac, cerebrovascular, or
renal complications. The mean follow-up was 3.4 years. EVARwas associated with increased mortality risk after adjusting for
age, ASA class, and comorbidities (hazard ratio, 1.50; 95% confidence interval, 1.07-2.12; P  .02). Kaplan-Meier survival
analysis showed a lower mortality rate for patients undergoing OR, which remained during follow-up (P  .001).
Conclusions: Elective OR of aortic aneurysms seems to have a better outcome compared with EVAR in this specific,
population-based, high-risk patient cohort after adjusting for covariates. We cannot confirm the benefit of EVAR from
previous registry studies with a similar high-risk definition. In clinical practice, OR may be at least as good as EVAR in
high-risk patients fit for surgery. (J Vasc Surg 2008;48:1382-9.)Endovascular aneurysm repair (EVAR) has rapidly
been integrated into routine clinical care worldwide for the
treatment of abdominal aortic aneurysm (AAA). The min-
imally invasive endovascular technology that was originally
intended to expand the treatment options for patients
deemed not good candidates for open surgical repair has
evolved substantially since its introduction.1 The European
randomized trials have provided evidence to show that
EVAR is associated with lower operative mortality than
open repair (OR) for treatment of AAA, but no difference
in midterm all-cause mortality.2,3
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1382Endovascular repair providing a less invasive alternative
has been considered an attractive treatment for high-risk
individuals with AAA. For patients who are unfit for OR,
the randomized EVAR-2 trial did not find a survival benefit
from EVAR compared with observation.4 However, high
crossover and procedural mortality rates have led to con-
troversy regarding the validity of this trial. Recent registry
reviews have shown that a selected cohort of high-risk
patients does well with EVAR compared with OR.5,6 This
study used a large, population-based prospective vascular
registry to determine the operative mortality and long-term
survival of elective EVAR compared with OR in high-risk
patients.
PATIENTS AND METHODS
Prospectively collected data from January 2000 to De-
cember 2006 for all patients who underwent elective EVAR
or OR of nonruptured infrarenal aortic aneurysms were
retrieved from the Swedish Vascular Registry (Swedvasc).
The registry has national coverage and includes all centers
performing EVAR and OR in Sweden: 36 hospitals were
performing OR and 17 hospitals performing EVAR. Pro-
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gether with postoperative 30-day and 1-year outcomes,
were registered. All patients were cross-matched with the
National Population Registry in March 2008 to update
mortality data, including date of death. Ethical approval for
the study was obtained from the Registry Steering Com-
mittee, which is the authority for research based on the
registry data. Each patient gave informed consent before
registration.
Sweden is divided in health service regions; each in-
cludes several counties and has a central hospital (university
hospital). Each county within a region has a county hospital
with up to 700 beds and with specialized and outpatient
facilities to serve a population of about 300,000. The
counties, in turn, are divided into districts; each has a
population of about 75,000 and is served by a district
hospital, which usually has 300 beds.
High-risk was defined, in line with recent registry stud-
ies,5,6 as age 60 years, American Society of Anesthesiol-
ogy (ASA) physical status classification 3 or 4, and at least
one cardiac, pulmonary, or renal comorbidity. ASA class 3
is a patient with severe systemic disease, and ASA class 4 is
a patient with severe systemic disease that is a constant
threat to life.7 Risk factors had the same definitions
throughout the study period. Cardiac disease is defined as
previous myocardial infarction, atrial fibrillation, heart fail-
ure, angina pectoris, coronary artery bypass graft surgery,
surgery for valvular heart disease or signs of myocardial isch-
emia on electrocardiogram; pulmonary disease, diagnosed
pulmonary disease such as chronic obstructive pulmonary
disease (COPD) or emphysema; renal insufficiency, a serum
creatinine level150mol/L (1.7mg/dL); hypertension,
diastolic blood pressure 110 mm Hg or antihypertensive
medication; diabetes mellitus, antidiabetic treatment with
diet, oral hypoglycemics, or insulin; cerebrovascular disease,
previous stroke or transient ischemic attack; previous vascular
surgery, previous open or endovascular procedure or amputa-
tion for peripheral vascular disease; hyperlipidemia, choles-
terol value2 standard deviations from normal value; statins,
statin treatment1month preoperatively; and smoking, reg-
ular smoking for the past 5 years.
The outcome measures were (1) 30-day operative
mortality, defined as death during the initial hospitaliza-
tion or death from any cause 30 days of the index
procedure; (2) postoperative complications within 30
days; and (3) long-term survival and all-cause mortality.
Statistical methods. Statistical analyses were per-
formed using SPSS software (SPSS Inc, Chicago, Ill). Con-
tinuous demographic variables were expressed as mean 
standard deviation and categoric variables as percentages.
The Mann-Whitney U test was used for continuous vari-
ables and the Pearson 2 test for categoric variables.
Kaplan-Meier curves, using the log-rank test, were used to
compare crude cumulative survival between EVAR and
OR. We compared OR and EVAR by calculating adjusted
hazard ratios (HR) using a Cox proportional hazards
model and adjusted for potential confounders (age at op-
eration, sex, and major comorbidities). Visual inspection oflog–log plots indicated that the proportional hazard as-
sumption was not violated. All HRs were reported with
95% confidence intervals (CIs). All tests were two-tailed,
with a P  .05 judged statistically significant.
RESULTS
Patient population. During the study period be-
tween 2000 and 2006, 3831 patients undergoing elective
repair of nonruptured infrarenal aortic aneurysmwere iden-
tified from the registry, of which 2831 had OR and 1000
had EVAR. The annual volume per hospital varied, with
OR at 0 to 52 cases per year and EVAR at 0 to 80 cases per
year. The yearly number of EVAR andOR is summarized in
Table I. The high-risk criteria narrowed the cohort to 700
patients, consisting of 217 EVAR and 483 OR.
Table II reports the baseline characteristics for all pa-
tients undergoing AAA repair, and Table III summarizes
data for the high-risk cohort. In the high-risk cohort, it is
noteworthy that EVAR patients were approximately 2 years
older and renal insufficiency and diabetes mellitus were
more common, and smoking was more prevalent in the OR
group. Half of the patients were taking statins and about
one-third had at least two high-risk comorbidities. About
two-thirds of EVAR procedures were performed at univer-
sity hospitals, and one-half of OR procedures were per-
formed at county hospitals. The mean follow-up time was
3.4  2.0 years for the high-risk cohort, and all patients
were followed up at least 1 year for survival.
Outcomemeasures. The respective crude 30-day oper-
ative and 1-year all-cause mortality rates for the 3831 treated
patients for EVAR vs OR were 1.8% vs 2.8% (P  .08) and
8.0% vs 7.2% (P  .15; Fig 1). There was no statistical
difference in 30-daymortality looking at type of hospital (OR:
university 3.0%, county 2.6%, district 3.0% [P .81]; EVAR:
university 2.1%, county 1.3%, district 0% [P .40]).
In the high-risk cohort (n  700), operative mortality
at 30-days was similar, with EVAR at 4.6% compared with
OR at 3.3% (P  .40; Fig 2). There was no significant
difference in reported 30-daymajor complications (Table IV).
More bleeding complications occurred in the EVAR group
and the OR group had more pulmonary complications; how-
ever, no difference was noted in cardiac, cerebrovascular, or
renal complications. A prolonged intensive care unit stay (5
Table I. The number of endovascular and open aortic
aneurysm repairs per year during the study period
Year EVAR OR
2000 103 416
2001 440 96
2002 395 101
2003 377 117
2004 449 145
2005 373 166
2006 381 272
Total 1000 2831
EVAR, Endovascular aneurysm repair; OR, open surgical repair.days) was more common in patients undergoing OR.
m repa
e 2 t
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significantly lower compared with 15.9% for EVAR (P 
.003; Fig 2). Kaplan-Meier survival analysis showed a lower
mortality rate for patients undergoing OR, which remained
during follow-up (P  .001). The estimated overall mor-
tality at 4 years was 26% for OR and 41% for EVAR. EVAR
was associated with increased mortality risk after adjusting
for age, ASA class, and comorbidities (HR, 1.50; 95% CI,
1.07-2.12; P  .02).
DISCUSSION
The significant mortality rate associated with aneurysm
repair and a trend toward minimally invasive techniques has
led to a rapid development of the endovascular technique
for AAA treatment. A natural indication for the endovascu-
lar approach was assumed to be patients who are at higher
risk fromOR.However, this population-based study found
a better long-term survival for high-risk patients undergo-
ing elective OR of nonruptured infrarenal aortic aneurysms
compared with EVAR. There was no difference between
treatments in terms of operative mortality and major 30-
day complications in the high-risk cohort.
When we compared our 30-day operative mortality rate
for the whole patient cohort with the randomized EVAR-12
and Dutch Randomised Endovascular Aneurysm Manage-
ment (DREAM)3 trials, there seemed to be a similar mor-
tality rate for EVAR (1.8% vs 1.2% to 1.7%) but a lower
mortality rate for OR (2.8% vs 4.6% to 4.7%) in our cohort.
Table II. Baseline characteristics for 3831 patients underg
during the study period
Characteristics EVAR (n 
Demographic factors
Age, mean (SD), y 74 
Age 60 y, % (No.) 96 (965/1
Male sex, % (No.) 86 (861/1
Setting, % (No.)
District hospital 6 (58/10
County hospital 23 (233/1
University hospital 71 (709/1
Risk factors, % (No.)
Cardiac disease 59 (548/9
Pulmonary disease 20 (178/8
Renal impairment 15 (134/8
Any of cardiac, pulmonary, renal 63 (629/1
Cerebrovascular disease 16 (145/8
Diabetes mellitus 13 (117/8
Hypertension 61 (555/9
Smoking 35 (308/8
Hyperlipidemia 38 (161/4
Statin treatment 17 (155/8
Previous vascular surgery 44 (179/4
ASA class
I 9 (58/66
II 52 (349/6
III 36 (240/6
IV 3 (19/66
ASA, American Anesthesiologist Association; EVAR, endovascular aneurys
aCalculated using the Mann-Whitney U test for continuous variables and thWe still found a short-term survival advantage for theEVAR group, but this did not reach significance because of
the low mortality rate for OR. When we looked at long-
term outcome, there was no difference between treatment
groups in the whole patient cohort, and the results were
similar compared with the large randomized studies. The
trend towards an early survival advantage for the EVAR
group was lost after 12 months of follow-up.
Two recent large registry studies examined the results
of EVAR and OR in high-risk patients with AAA.5,6 Using
the Department of Veteran Affairs National Surgical Qual-
ity Improvement Program database, Bush et al5 identified a
high-risk cohort of 2368, including veterans (99% men)
aged60 years, ASA classification 3 or 4, and comorbidity
variables of history of cardiac, respiratory, or hepatic dis-
ease; cardiac revascularization, renal insufficiency, or low
serum albumin level. They found the EVAR mortality rate
to be significantly lower than OR at 30 days (3.4% vs 5.2%)
and at 1 year (9.5% vs 12.4%).
The Outcomes Committee of the Society for Vascular
Surgery selected a cohort of 626 high-risk patients from five
multicenter investigational device exemption clinical trials
leading to Food and Drug Administration (FDA) approval.6
High-risk in this study was defined as age 60 years with
aneurysm size 5.5 cm plus at least one cardiac, pulmo-
nary, or renal comorbidity. When they compared the
EVAR and OR groups, they found no significant difference
in operative mortality (EVAR, 2.9%; OR, 5.1%), AAA-
related death, or overall survival at 1 year (EVAR, 87%; OR,
endovascular or open abdominal aortic aneurysm repair
0) OR (n  2831) Pa
71  8 .0001
92 (217/2831) .0001
82 (2308/2831) .001
12 (332/2831)
50 (1412/2831) .0001
38 (1087/2831)
53 (1419/2682) .001
19 (497/2640) .44
10 (257/2616) .0001
58 (1636/2831) .005
14 (373/2627) .11
8 (202/2618) .0001
62 (1661/2663) .42
50 (1254/2534) .0001
43 (562/1319) .092
14 (380/2628) .043
44 (501/1150) .43
10 (208/2033)
57 (1162/2033) .016
31 (627/2033)
2 (36/2033)
ir; OR, open surgical aneurysm repair.
est for categoric variables, unless otherwise specified.oing
100
7
000)
000)
00)
000)
000)
28)
90)
91)
000)
83)
88)
12)
77)
24)
98)
07)
6)
66)
66)
6)86%) or 4 years (EVAR, 56%; OR, 66%). Limitations in this
e  t
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and 75% of patients classified as high-risk had only one
comorbidity, whereas 1% had all three comorbidities.
Smaller retrospective registry studies in high-surgical-
Fig 1. Kaplan-Meier curve of survival for all patients with abdom-
inal aortic aneurysm undergoing open (OR, dashed line) or endo-
vascular (EVAR, solid line) repair. Error bars denote 95% confi-
dence intervals.
Table III. Baseline characteristics for 700 high-risk patien
aneurysm repair during the study period
Variables EVAR (n  21
Demographics
Age, mean (SD), y 75  6
Male sex, % (No.) 85 (184/217
Setting, % (No.)
District hospital 4 (8/217)
County hospital 34 (74/217)
University hospital 62 (135/217
Risk factors, % (No.)
Cardiac disease 87 (188/215
Pulmonary disease 32 (69/213)
Renal impairment 26 (56/213)
High-risk comorbidity, No.b
1 62 (134/217
2 32 (70/217)
3 6 (13/217)
Cerebrovascular disease 21 (44/212)
Diabetes mellitus 16 (33/211)
Hypertension 72 (154/214
Smoking 34 (66/192)
Hyperlipidemia 47 (40/85)
Statin treatment 47 (62/133)
Previous vascular surgery 22 (47/213)
ASA class
III 92 (199/217
IV 8 (18/217)
ASA, American Anesthesiologist Association; EVAR, endovascular aneurys
aCalculated using the Mann-Whitney U test for continuous variables and th
bNumber of cardiac, pulmonary and renal risk factors present.risk patients undergoing EVAR have shown operative mor-tality rates of 4.3% to 5% and a 3-year survival of 70% to
85%.8,9 A recent analysis of patients from the United King-
dom (UK) EVAR trials, using a modified version of the
Customized Probability Index to allocate fitness scores for
Fig 2. Kaplan-Meier curve of survival for high-risk patients with
abdominal aortic aneurysm undergoing open (OR, dashed line) or
endovascular (EVAR, solid line) repair. Error bars denote 95%
confidence intervals.
dergoing endovascular or open abdominal aortic
OR (n  483) Pa
73  6 .0001
83 (401/483) .56
14 (65/483)
51 (248/483) .0001
35 (170/483)
88 (414/473) .98
34 (159/463) .62
19 (86/455) .030
67 (326/483) .24
29 (138/483)
4 (19/483)
18 (81/454) .37
9 (42/454) .015
71 (327/461) .78
52 (229/440) .0001
59 (136/231) .061
50 (115/228) .48
18 (80/455) .17
95 (459/483) .087
5 (24/483)
ir; OR, open repair.
est for categoric variables, unless otherwise specified.ts un
7)
)
)
)
)
)
)
m repa
2all patients, found EVAR convincingly to favor only the
resutu
cardia
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midterm survival, no benefit was found for either EVAR or
OR across all fitness scores.
The EVAR 2 trial included 338 patients deemed unfit
for OR, with a minimum age of 60 years and aneurysm
diameter 5.5 cm, and is the only randomized trial that
compared EVAR with observation.4 The study reported no
difference in all-cause or AAA-related mortality with a
trend favoring observation. The trial was complicated by
long delays in EVAR after randomization and a 27% patient
crossover rate from the no intervention group. The 30-day
operative mortality rate in the EVAR group for elective cases
was 7%, and the overall mortality rate after 4 years was 64%.
When compared with the two large registry studies
from Bush et al5 and Sicard et al,6 the 30-day operative
mortality rate in the present study seems to be higher for
EVAR and lower for OR. The lower operative mortality for
OR in general might reflect a centralization of AAA treat-
ment to larger hospitals and procedures performed pre-
dominantly by vascular surgeons. Other possible explana-
Table IV. Reported 30-day complications and freedom fr
aneurysm group
Variable OR (n  483)
30-day complicationsb
Bleeding 5.0 (24/47
Ileus 1.0 (5/479
Bowel ischemia 2.5 (12/47
Bowel resection 0.4 (2/479
Superficial infection 2.9 (14/47
Deep infection 0.4 (2/479
Sepsis 0.4 (2/479
Wound dehiscence 4.0 (19/47
Resuture of wound 3.1 (15/47
Drainage 0.6 (3/479
Graft occlusion 3.5 (17/47
Distal embolization 4.2 (20/47
Fasciotomy 0.8 (4/479
Major amputation 0.8 (4/479
Minor amputation 0.4 (2/479
Relaparotomy 2.7 (13/47
Cerebrovascular 1.9 (9/479
Cardiac 6.5 (31/47
Pulmonary 6.9 (33/47
Renal 4.2 (20/47
Venous thromboembolism 0.2 (1/479
Multiple organ failure 1.7 (8/479
ICU stay 5 days 6.3 (30/47
Freedom from 30-day complication
No surgical complicationc 78 (374/4
No general complicationd 76 (365/4
No reoperatione 90 (432/4
No complication or reoperation 62 (298/4
No major complicationf 81 (386/4
EVAR, Endovascular aneurysm repair; ICU, intensive care unit; OR, open
aP was calculated using 2 test.
bRegistration of complications was missing in 4 OR patients and 11 EVAR
cSurgical complication includes bleeding, ileus, superficial and deep infectio
dGeneral complication includes cerebrovascular, cardiac, pulmonary, renal,
eReoperation includes minor and major amputations, drainage, fasciotomy,
fMajor complication includes bowel ischemia or resection, cerebrovascular,tions are selection of patients with a better risk profile, andimproved anesthesia and surgical techniques as well as
postoperative care. Most of the EVAR procedures were
performed at university hospitals. The early survival advan-
tage usually seen for EVARwas not present in this high-risk
cohort. We do not believe that the loss of early survival
advantage for EVAR is explained by learning curve because
EVAR was introduced in the mid-1990s in Sweden. Also,
low-volume centers did not in general have a worse 30-day
mortality rate compared with high-volume centers (data
not shown).
The overall 1-year mortality in the present study is
higher for EVAR compared with the other registry studies.
This was clearly surprising given that we used the same
high-risk definitions. The advantage of this population-
based registry is its external validity (ie, the applicability of
its results to the defined population). Looking at the EVAR
2 trial, the 30-day and 1-year mortality rates for EVAR in
our study were lower. However, we do not intend to
compare our results with the EVAR 2 trial, which included
a different subpopulation of patients, those unfit for OR.
0-day complications in the high-risk abdominal aortic
o. EVAR (n  217), % (No.) Pa
9.2 (19/206) .037
0 (0/206) .14
1.5 (3/206) .39
1.0 (2/206) .38
2.4 (5/206) .72
0.5 (1/206) .90
1.0 (2/206) .38
0.5 (1/206) .013
0 (0/206) .010
1.5 (3/206) .28
4.9 (10/206) .42
2.9 (6/206) .43
0 (0/206) .19
1 (2/206) .86
0 (0/206) .35
0.5 (1/206) .059
0.5 (1/206) .16
6.3 (13/206) .94
1.0 (2/206) .001
5.8 (12/206) .35
0 (0/206) .51
1.5 (3/206) .84
1.5 (3/206) .007
80 (165/206) .44
82 (168/206) .12
96 (197/206) .017
64 (132/206) .64
85 (175/206) .17
al aneurysm repair.
ts.
ft occlusion, wound dehiscence, distal embolization, and bowel ischemia.
multiorgan failure, venous thromboembolism, and ICU stay 5 days.
re of wound, bowel resection, and relaparotomy.
c, multiorgan failure, pulmonary, renal, sepsis, or major amputation.om 3
, % N
9)
)
9)
)
9)
)
)
9)
9)
)
9)
9)
)
)
)
9)
)
9)
9)
9)
)
)
9)
79)
79)
79)
79)
79)
surgic
patien
n, gra
sepsis,Patients in the registry studies undergoing EVAR could be
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for OR. The registry studies are also lacking a surveillance
arm for comparison.
Endovascular repair was associated with increased mor-
tality risk after adjusting for age, ASA class, and risk factors.
Cardiac complications are the most common serious peri-
operative complication of EVAR and the most common
cause of late death.4 There was no difference in cardiac risk
factors or ASA classification between the EVAR and theOR
group in this registry, but we did not have access to the
cause of death. All-cause mortality was reported, which is
very accurate due to every citizen’s personal identity code
registered in the National Population Registry. Regarding
aneurysm-related death, we believe it is an unreliable end
point considering today’s low autopsy rate and inaccurate
recordings outside the hospital. Aneurysm-related deaths
are not common beyond the perioperative period, and
patients generally die from causes not related to their
aneurysm.5 There was also no significant difference in
30-day major complications between treatment groups.
We can only speculate about causes responsible for the
increased 1-year mortality rate after EVAR in this cohort.
The effect of contrast-induced nephropathy (CIN) in high-
risk patients undergoing EVAR is not known. This is an
important complication that accounts for a significant
number of cases of hospital-acquired renal failure, with
adverse effects on prognosis and health care costs.11 The
EVAR procedure itself, with intraluminal manipulation of
the renal arteries, device placement across the renal ostia,
and contrast administration during the procedure, as well as
repeated contrast-infused computed tomography surveil-
lance could possibly all together worsen renal function in
high-risk patients. A higher incidence of in-hospital and late
cardiovascular events as well as death has been reported
when CIN develops.12 At 1 year, the cumulative rate of
major adverse cardiac events was significantly higher in
patients with CIN according to a study by Dangas et al.13
The risk of CIN is elevated and of clinical importance in
patients with chronic kidney disease, particularly when
diabetes mellitus is also present. In this study, it is notewor-
thy that high-risk EVAR patients had significantly more
diabetes mellitus and renal insufficiency than OR patients.
Mills et al14 recently showed significantly greater renal
function decline for EVAR compared with OR during
long-term follow-up. Age 70 years strongly correlated
with serial renal function decline in all patients. A decreased
glomerular filtration rate in elderly patients is an indepen-
dent predictor of adverse outcomes, including not only
complications related to chronic kidney disease but also
cardiovascular events and death.15
We did not have information on size of the aneurysms
or complexity of aneurysm anatomy. Zarins et al16 reported
that patients with large AAAs (6.0 cm) have shorter life
expectancy and have a higher risk of rupture, surgical
conversion, and aneurysm-related death after EVAR com-
pared with patients with smaller aneurysms. The general
consensus in Sweden is to perform AAA repair when the
aneurysm has reached a diameter of 5.0 to 5.5 cm, and wehave no reason to believe that the size would be different
between the treatment groups.
Several validated scoring systems have been developed
for risk stratification of aneurysm repair.17 However, there
is no validated scoring system for high-risk patients with
AAA. Risk factors associated with excessive surgical risk in
patients with AAA and frequent variables in scoring systems
are age and cardiac, pulmonary, and renal comorbidities.18
The definition of high-risk patients has, unfortunately,
varied in different studies. The differences in outcome
among studies might reflect the lack of consistent definition
of high-risk patients. For comparison reasons, we tried to
use definitions similar to those used in previous registry
studies, including age, ASA class, and cardiac, pulmonary,
and renal risk factors. The EVAR 2 trialists took a pragmatic
approach to fitness for OR but noted details of respiratory,
renal, and cardiac risk. A problem with the ASA classifica-
tion is, despite its simplicity, a possibility for wide interpre-
tation by the surgeon entering the variable. A consistent,
internationally accepted definition of risk factors would
facilitate comparisons between registries and trials in the
future.
These data represent all hospitals performing AAA re-
pair covering a population of 9 million. Registry data have
several inherent limitations, but Swedvasc has been vali-
dated on several occasions.19-21 Validity control has been
performed comparing data with computerized anesthesia
registries and by refilling random samples of protocols.
More than 90% of open and endovascular arterial proce-
dures performed in the country are reported to the registry
compared with the National Inpatient Registry that is used
for health care development, research, and planning. Data
monitoring by independent outside assessors have not been
undertaken. Accurate updated survival data are obtained
every week by cross checking with the National Population
Registry.
The registry has no data on patients not undergoing
EVAR or OR. Different selection criteria for surgery could
possibly indicate that less healthy patients are not chosen
for OR. However, the annual operative frequency for AAA
repair is not lower in Sweden compared with several other
countries. Baseline risk factors are prospectively registered,
but the reliability depends on the accuracy of the responsible
surgeonwhile completing the protocol.Most risk factors have
a 95% registration rate. Analyses of cost-effectiveness and
quality of life issues were not performed in this study.
CONCLUSION
Patients deemed fit for OR have a better long-term
outcome compared with patients deemed fit and suitable
for EVAR in this high-risk cohort. We cannot confirm the
benefit of EVAR from previous registry studies with a
similar high-risk definition. In clinical practice, OR may be
at least as good as EVAR in high-risk patients fit for surgery.
If the patient is at lower risk, EVAR tends to reduce
operative death, but this early survival advantage disappears
after 1 year. We believe that EVAR for infrarenal AAAs is
the first choice in line with the large randomized studies,
JOURNAL OF VASCULAR SURGERY
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that benefit more fromOR than EVAR. From this study we
cannot draw any conclusions about patients unfit for sur-
gery. Improved criteria for patient selection, including risk
stratification of consistent defined comorbidities, will bet-
ter help us to find those patients that will benefit from open
or endovascular AAA treatment.
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The Swedish Vascular Registry (Swedvasc) is a long standing
national project used for auditing outcome of a variety of vascular
procedures.1 The authors for the Swedish Vascular Registry
(Swedvasc) have assessed the outcome of endovascular repair in
patients at high-risk for surgical treatment of their abdominal
aortic aneurysm in comparison to open surgery. A comparison ofof co-morbid factors between treatment groups. The authors
selected two studies with a similar design for comparison with their
own series. The first study, a Veterans Administration study, was
reported by Bush et al and the second by Sicard et al.2,3 These US
studies both concluded from their operative and late mortality data
that patients with infrarenal abdominal aortic aneurysm with con-
siderable medical co-morbidities benefit from and should be con-
